An NDM-Producing Escherichia coli Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Towards Pan-β-Lactam Resistance

  19 May 2023

Cefiderocol and ceftazidime-avibactam plus aztreonam (CZA-ATM) are preferred treatment regimens for NDM-producing infections.

We report the case of a United States patient who traveled to India to receive a renal transplant. He subsequently experienced pyelonephritis by an NDM-producing Escherichia coli. Broth microdilution and the broth disk elution method indicated resistance to all β-lactams, including cefiderocol and CZA-ATM. WGS investigations were undertaken to identify resistance mechanisms.

This is the first clinical case of a United States patient harboring an NDM-producing isolate exhibiting resistance to all available β-lactam agents. 

 

Author(s): Patricia J Simner, Yehudit Bergman, Rick Conzemius, Emily Jacobs, Tsigereda Tekle, Stephan Beisken, Pranita D Tamma
Effective Surveillance  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

LifeArc

Antimicrobial Resistance Fighter Coalition

Bangalore Bioinnovation Centre

INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS





AMR NEWS

Every two weeks in your inbox

Because there should be one newsletter that brings together all One Health news related to antimicrobial resistance: AMR NEWS!

Subscribe

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!

Keep me informed